Evolve BioSystems & UC Regents v. Abbott Laboratories: Mixed Judgment After 5+ Years
Evolve BioSystems (now Infinant Health) and the Regents of the University of California clashed with Abbott Laboratories over two infant prebiotic patents covering synthetic human milk oligosaccharide technology used in products including Similac and EVIVO. After 1,981 days of litigation, the Illinois Northern District Court entered a split judgment — neither party achieving a clean victory.
A 5-Year Patent Battle Over Infant Prebiotic Formulas Ends in a Split Verdict
Filed in August 2019 in the Northern District of Illinois, this case pitted Evolve BioSystems (now trading as Infinant Health) and the Regents of the University of California against Abbott Laboratories over two patents — US9200091B2 and US8197872B2 — covering synthetic prebiotic compositions derived from human milk oligosaccharides. The disputed products included Abbott’s Similac® prebiotic human milk products, Evolve’s EVIVO®, and Evolve’s Similac Probiotic Tri-blend, placing the commercial stakes squarely in the fast-growing infant nutrition sector.
The case resolved via cross-motions for summary judgment decided on January 7, 2025, with final judgment entered January 31, 2025. The outcome was distinctly split: all four counts in the plaintiffs’ amended complaint were decided in Abbott’s favor, while Abbott’s Counterclaims I–IV were decided in plaintiffs’ favor. Abbott prevailed on its Counterclaims VI and VII, and Counterclaim VIII was dismissed without prejudice as moot. Plaintiffs’ own Counterclaims I–III were decided for Abbott; Counterclaims IV–V were dismissed without prejudice by agreement.
The 1,981-day duration suggests protracted claim construction disputes and voluminous summary judgment briefing typical of cases involving university-originated biotech patents with broad foundational claims. The stay of costs and fee deadlines pending appeal signals that both sides likely view further proceedings as viable, leaving the commercial and IP landscape in this infant prebiotic space unsettled. The precise scope of each party’s remaining exposure is not fully determinable from the public docket alone.
Filing to Mixed Judgment in 1981 days
1,981 days — nearly 5.5 years, well above the median patent case duration of ~2.5 years in district courts
Mixed judgment explained: what each party won and lost
Cross-motions for summary judgment produced a split ruling
A mixed judgment on cross-motions for summary judgment means the court found sufficient undisputed facts to rule for each side on different claims — without a jury trial. Neither party obtained a complete victory. The court’s January 7, 2025 order resolved all substantive counts, leaving only costs and fees stayed pending appeal. This outcome is legally distinct from a settlement: it reflects the court’s merits analysis on each discrete count.
Summary judgment — mixedEvolve and UC Regents lose on complaint but partially defeat Abbott’s counterclaims
Judgment entered against plaintiffs on all four counts of their amended complaint — the core infringement or declaratory claims they brought. However, plaintiffs prevailed against Abbott on Counterclaims I–IV, suggesting partial success in defending against Abbott’s affirmative assertions. Plaintiffs’ own Counterclaims I–III were decided against them, and Counterclaims IV–V were dismissed by agreement. The net position is a partial win on defense, but a loss on their offensive claims.
Partial plaintiff defeatAbbott wins all complaint counts but loses on key counterclaims
Abbott secured judgment on all four complaint counts — effectively defeating plaintiffs’ primary claims. Abbott also prevailed on its Counterclaims VI and VII. However, Abbott lost on Counterclaims I–IV, indicating the court rejected certain of Abbott’s affirmative assertions against the patents or parties. Counterclaim VIII was dismissed as moot. The fee and cost stay suggests Abbott may face continued exposure depending on the scope of any appeal.
Partial defendant winHMO patent landscape remains contested — appeal risk is live
The stayed costs and fee deadlines explicitly anticipate appeals, meaning neither Similac® nor EVIVO® product teams can treat this as a final IP clearance event. The mixed outcome on multiple counterclaims involving university-originated prebiotic patents may complicate freedom-to-operate assessments across the infant formula sector. Competitors in the human milk oligosaccharide space should monitor any Federal Circuit appeal closely, as the underlying patent scope questions remain commercially material.
Appeal risk — sector watchFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Evolve BioSystems, Inc. | Company | Infant microbiome biotech and UC Regents — co-holders of infant prebiotic HMO patentsSearch in Eureka ↗ |
| Co-Plaintiff | Regents of the University of California | Individual | Search in Eureka ↗ |
| Defendant | Abbott Laboratories, Inc. | Company | Abbott Laboratories, Inc. — global infant nutrition manufacturer, maker of Similac® productsSearch in Eureka ↗ |
| Plaintiff counsel | Arturo Jorge Gonzalez | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Chan Q. Vu | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | David Alan Deschepper , Jr. | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Hancock | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | John C. Ellis | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew Alan Chivvis | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew I Kreeger | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Parisa Jorjani | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Soo Jeong Park | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stephanie L. Blij | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Tait Karsten Anderson | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Todd H. Flaming | Attorney | Counsel for Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Ellis Legal P.C. | Law Firm | Representing Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morrison & Foerster LLP | Law Firm | Representing Evolve BioSystems, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Todd Flaming LLC | Law Firm | Representing Evolve BioSystems, Inc.Search in Eureka ↗ |
| Defendant counsel | Charles Bennett Klein | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Dan Huy Hoang | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Devin Garrity | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Katherine Laura Kyman | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Kevin John Boyle | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael A. Meneghini | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael R. Rueckheim | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Nimalka Ratnavali Wickramasekera | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert N. Kang | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen Victor D’Amore | Attorney | Counsel for Abbott Laboratories, Inc.Search in Eureka ↗ |
| Defendant law firm | Winston & Strawn, LLP | Law Firm | Representing Abbott Laboratories, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Illinois Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict’s split structure — plaintiffs losing all complaint counts while defeating Abbott on Counterclaims I–IV — reflects a court that found the record insufficient to fully vindicate either party’s affirmative positions. The dismissal of multiple counterclaims without prejudice (Abbott’s VIII; plaintiffs’ IV and V) preserves optionality for both sides without merits adjudication on those specific claims. The explicit stay of costs and fees pending appeal is a strong procedural indicator that further litigation in this matter is anticipated. The Basis of Termination is formally recorded as ‘Mixed Judgment,’ which is atypical and underscores the complexity of the claim matrix resolved here.
US9200091B2 & US8197872B2 — Infant prebiotic human milk oligosaccharide compositions
US9200091B2 (App. No. 13/809,556) and US8197872B2 (App. No. 12/121,683) are University of California-originated patents covering synthetic prebiotic compositions based on human milk oligosaccharides (HMOs), specifically designed to support infant gut microbiome development. These patents sit at the foundational layer of the emerging HMO ingredient market, where the scientific basis for early-life microbiome colonisation is well-established and commercially significant. The application dates suggest priority from the mid-to-late 2000s, giving these patents substantial remaining term through the 2020s.
The strategic value of these patents derives from their position as potential gatekeepers for any infant formula manufacturer seeking to incorporate synthetic prebiotic HMO ingredients — a segment now attracting investment from Abbott, Nestlé, and Danone, among others. University co-ownership via UC Regents adds an additional licensing dynamic: commercial exploitation typically requires co-owner consent, and enforcement requires either joint standing or assignment. For sector participants, the outcome of any Federal Circuit appeal will materially determine whether these patents function as meaningful barriers or can be designed around.
Should you run an FTO against US9200091B2 and US8197872B2?
Any company developing or commercialising synthetic prebiotic infant formula products incorporating human milk oligosaccharides — whether as a brand, ingredient supplier, or private-label manufacturer — should treat these patents as active FTO concerns. The district court’s mixed judgment means neither patent was cleanly invalidated, and the appeal posture means claim scope is not yet final. Companies entering the HMO infant nutrition segment without current FTO clearance face meaningful infringement risk until appellate proceedings conclude.
PatSnap Eureka’s FTO Search Agent can map the full independent claim landscape of US9200091B2 and US8197872B2 against your product formulation, identify relevant prior art that was or was not before the district court, and flag co-pending continuation or divisional applications that may not yet be in litigation. Given the UC Regents co-ownership structure, Eureka can also surface related university licensing activity and identify whether design-around pathways exist within the HMO compositional space.
Run a freedom-to-operate analysis on US9200091B2 to assess your product’s exposure
Run FTO in Eureka →Similar HMO and infant nutrition patent cases in U.S. district courts
Explore comparable patent disputes involving human milk oligosaccharide and infant prebiotic technology litigated across U.S. district courts, including N.D. Illinois.
What this case signals for the infant prebiotic and HMO patent landscape
A mixed judgment between Evolve/UC Regents and Abbott sends complex signals for the infant nutrition IP ecosystem.
University co-plaintiff structures complicate licensing negotiations
Having the UC Regents as a co-plaintiff alongside a commercial entity creates divided ownership dynamics that typically complicate settlement, licensing, and any post-judgment enforcement. Competitors observing this case should note that university-originated patents in the HMO space may require dual-party engagement in any licensing or freedom-to-operate strategy.
Mixed judgments increase appeal probability — monitor the Federal Circuit docket
When neither party achieves a clean win at the district court level, both sides retain strong incentives to appeal. The explicit stay of fees pending appeal in this case reinforces that expectation. Patent counsel in the infant nutrition sector should set Federal Circuit monitoring alerts for case No. 1:19-cv-05859 to track whether key claim scope rulings are affirmed, reversed, or narrowed.
Evolve v Abbott — key questions answered
The Northern District of Illinois entered a mixed judgment on January 31, 2025, following cross-motions for summary judgment. Judgment was entered for Abbott on all four counts of plaintiffs’ complaint, for plaintiffs on Abbott’s Counterclaims I–IV, and for Abbott on Counterclaims VI–VII. Multiple additional counterclaims were dismissed without prejudice. Costs and fees are stayed pending any appeal.
Two patents were asserted: US9200091B2 (App. No. 13/809,556) and US8197872B2 (App. No. 12/121,683), both originating from the University of California and covering synthetic prebiotic human milk oligosaccharide compositions used in infant nutrition products.
The products at issue included Abbott’s Similac® synthetic prebiotic human milk products, Evolve BioSystems’ EVIVO® prebiotic product, and Evolve’s Similac Probiotic Tri-blend. The dispute centred on the use of synthetic HMO-based prebiotic technology across these infant nutrition formulas.
The 1,981-day duration is consistent with complex biotech patent cases involving university-originated patents, multiple asserted claims, cross-claim structures, and extensive summary judgment briefing. Cases involving HMO technology with broad foundational claims typically require extended claim construction and expert proceedings before the court can resolve them on summary judgment.
Yes. The court explicitly stayed deadlines for costs and attorney’s fees pending any appeals, indicating anticipated further proceedings. Both parties have arguable grounds for appeal given the split outcome. Any appeal would proceed to the U.S. Court of Appeals for the Federal Circuit, which has exclusive jurisdiction over patent case appeals from U.S. district courts.
PatSnap Eureka searches patents and litigation data to answer instantly.